Vivos Therapeutics, Inc. (VVOS)

Market Cap	14.58M
Revenue (ttm)	15.03M
Net Income (ttm)	-11.14M
Shares Out	5.89M
EPS (ttm)	-2.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97,020
Open	2.440
Previous Close	2.300
Day's Range	2.440 - 2.520
52-Week Range	1.910 - 6.280
Beta	7.28
Analysts	Strong Buy
Price Target	6.10 (+146.47%)
Earnings Date	May 13, 2025

About VVOS

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and s...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 109
• Stock Exchange: NASDAQ
• Ticker Symbol: VVOS
• Website: https://www.vivos.com

Financial Performance

In 2024, Vivos Therapeutics's revenue was $15.03 million, an increase of 8.91% compared to the previous year's $13.80 million. Losses were -$11.14 million, -18.02% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for VVOS stock is "Strong Buy." The 12-month stock price forecast is $6.1, which is an increase of 146.47% from the latest price.

Price Target

$6.1

(146.47% upside)

Analyst Consensus: Strong Buy